Articles

In patients with biliary tract cancer, EGFR amplifications and FGFR3 fusions may serve as important predictive biomarkers and as potential targets for anticancer therapy in the future. Read More ›

An analysis of circulating tumor DNA–based comprehensive genomic profiling to detect actionable rearrangements in patients with gastrointestinal malignancies was presented by Pashtoon Kasi, MD, MS. Read More ›

Two phase 1a/1b dose-escalation/expansion trials investigated the efficacy and safety of MDM2-p53 antagonist BI 907828 in patients with advanced biliary tract cancer. Read More ›

CTX-009 in combination with paclitaxel showed encouraging efficacy in patients with advanced biliary tract cancer. Read More ›

Gunagratinib is being investigated in an ongoing phase 2a dose-expansion study in patients with cholangiocarcinoma. Read More ›

Results of the SWOG 1815 study failed to demonstrate a benefit with the addition of nab-paclitaxel to gemcitabine/cisplatin (GemCis) versus GemCis alone. Read More ›

In the JCOG1202 subgroup analysis, researchers analyzed risk factors for early relapse in patients with biliary tract cancer undergoing surgical resection. Read More ›

Researchers aimed to assess characteristics, outcomes, and genomic profiles of long-term survivors treated with durvalumab plus gemcitabine/cisplatin (GemCis) or placebo plus GemCis in the TOPAZ-1 trial. Read More ›

IMbrave 151 examined the efficacy of the PD-L1 inhibitor atezolizumab with or without the VEGF inhibitor bevacizumab, and gemcitabine/cisplatin as first-line treatments in patients with advanced biliary tract cancer. Read More ›

A single-arm, phase 2 study investigated the safety and efficacy of second-line nab-paclitaxel combined with the anti–PD-1 antibody sintilimab in patients with advanced biliary tract cancer. Read More ›